Clidets

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clidets

What is Clidets? Defining the Topical Antibacterial Agent

Property Description
Active ingredient Clindamycin Phosphate
Form Topical Solution, Gel, or Lotion
Pharmacological class Lincosamide Antibiotic
Common use Topical Antimicrobial Therapy
Origin Semi-synthetic

Defining Clidets: Class and General Purpose

Clidets is a semi-synthetic antibiotic that belongs to the lincosamide pharmacological class, utilized for its activity against certain bacteria associated with dermatological conditions. It is classified as a specialized, single-ingredient dermatological preparation. The agent's primary function is to provide topical antimicrobial therapy, aimed at controlling the microbial load on the skin that contributes to localized inflammatory conditions. Unlike systemic antibiotics, Clidets is designed exclusively for localized application, a factor that positions it as a targeted approach for skin surface treatment.


Composition and Origin: The Clindamycin Phosphate Pro-Drug

The core active ingredient in the Clidets formulation is Clindamycin Phosphate, which is defined as a pro-drug—a precursor utilized to enhance stability and delivery into the skin layers. This phosphate ester is metabolized into the active antibacterial molecule, Clindamycin. The compound is a semi-synthetic antibiotic derived from the naturally occurring lincomycin, a modification intended to improve its therapeutic properties. The most common dosage form of Clidets is typically a topical solution or gel, designed for topical administration.


Understanding the Type: A Specialized Topical Agent

Clidets is intended for topical administration, distinguishing it from internal medicines. This formulation type concentrates the antibacterial effect where it is applied. The fundamental principle is that the active Clindamycin works by disrupting the protein production necessary for bacterial survival, achieving a bacteriostatic effect that manages the proliferation of susceptible organisms. This specialized design allows for delivery to the target area without requiring systemic distribution.

What side effects are possible with Clidets?

Possible Side Effects and Safety Information

The safety profile of Clidets (Clindamycin Phosphate Topical) is primarily defined by local reactions at the application site and specific warnings regarding systemic risks associated with the antibiotic class. This information is derived from official regulatory documents and structured by system-organ class and frequency.


Officially Documented Adverse Reactions

Adverse reactions are classified into System-Organ Classes (SOCs). The most common reactions fall under Skin and Subcutaneous Tissue Disorders.

Classification (Frequency) Documented Adverse Reactions (SOC: Skin)
Very Common (ge 10%) Skin dryness, erythema (redness), itching, oily skin (seborrhea)
Common (1% to 10%) Skin peeling, burning sensation, irritation, contact dermatitis

Safety Considerations and Warnings

Although Clidets is applied topically, a low potential for systemic absorption exists, leading to documented risks under Gastrointestinal Disorders. The most significant safety concern is the possibility of developing Pseudomembranous Colitis, a serious adverse reaction related to antibiotic use.

This medicine is contraindicated in individuals with a history of sensitivity to clindamycin or lincomycin, or a prior history of specific bowel diseases, including antibiotic-associated colitis, ulcerative colitis, or regional enteritis. Furthermore, safety and efficacy have not been established in pediatric patients under 12 years of age.

A key regulatory safety note indicates that if severe gastrointestinal issues occur, such as diarrhea or colitis, onset may be delayed and appear up to several weeks following the cessation of therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Clidets (clindamycin phosphate topical) addresses the potential for systemic effects due to the absorption of the active ingredient through the skin. This absorption carries the risk of systemic toxicity, which is the primary concern in overdose scenarios.


Documented Manifestations and Emergency Action

Classification Official Regulatory Statement
Documented Manifestations Gastrointestinal toxicity, including diarrhea, bloody diarrhea, and the development of colitis
Severe Outcomes The potential for pseudomembranous colitis, which has been documented as a complication that may end fatally

Official Response and Help-Seeking Mandates

Discontinuation of the product is an immediate action mandated by regulatory authorities if significant diarrhea develops. Management of overdose is limited to general symptomatic and supportive measures because no specific antidote is known for clindamycin toxicity.

Emergency medical care is required if severe systemic symptoms, such as persistent or bloody diarrhea, or severe abdominal cramps, are experienced. Additionally, if accidental contact with sensitive surfaces, such as the eyes or mucous membranes, occurs, the official instruction is to bathe the affected area with copious amounts of cool tap water.

Therapeutic Uses of Clidets

The Role in Managing Inflammatory Acne Vulgaris

Clidets is commonly used in clinical settings to address acne vulgaris, particularly cases presenting as mild to moderate inflammatory acne. The medication may assist with managing the symptoms associated with bacterial activity, which often manifest as papules (red bumps) and pustules (pus-filled lesions). This approach helps ease the overall symptom burden associated with this common condition.

The therapeutic benefit is relevant for easing symptoms that include localized redness (erythema), swelling, and recurrent inflammatory episodes. This medicine is considered relevant in situations requiring long-term, supportive treatment, as it plays a role in managing the symptoms associated with bacterial activity. This use assists with maintaining functional stability when symptoms are recurrent, supporting general well-being during symptomatic phases.

“The therapeutic role of Clidets may be to provide supportive relief in conditions characterized by periods of heightened symptoms.”

Quick Fact: Support for Inflammatory Blemishes The medication contributes to improved day-to-day comfort by helping to ease the symptomatic manifestations of redness and swelling during active breakouts.

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Contraindication Information

Clidets (Clindamycin) is an antibiotic treatment typically reserved for serious infections where less toxic agents are inappropriate, as its use is associated with a risk of severe colitis. This drug should not be used for non-bacterial infections, such as most upper respiratory tract infections, or for the treatment of meningitis.

Classification Population/Condition
Contraindicated Individuals with a history of hypersensitivity or allergy to clindamycin, lincomycin, or any excipient in the formulation.
Use Not Established Safety and effectiveness in pediatric patients under the age of 12 have not been fully established, though use in infants and children is permitted with caution and close monitoring.
Requires Caution Individuals with a history of gastrointestinal disease, particularly colitis, or atopic conditions. Patients with pre-existing renal or hepatic impairment should be closely monitored, and dosage adjustments may be needed in severe cases.
Pregnancy/Lactation Systemic use during the second and third trimesters of pregnancy is generally not associated with congenital abnormalities. However, it should only be used if clearly needed. Due to the potential for adverse effects on the infant's gut flora, the need for continued breastfeeding should be carefully weighed against the mother's clinical need for the drug.

Note: Because Clindamycin does not diffuse adequately into the cerebrospinal fluid, it is officially restricted from use in meningitis. Patients with certain rare hereditary problems like galactose intolerance should also avoid this medicine due to capsule excipients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Clidets (Clindamycin Phosphate topical) focuses on officially documented patterns that require specific restrictions or monitoring. The minimal systemic absorption of the topical formulation generally limits the risk of systemic pharmacokinetic interactions.

Documented Interaction Patterns

Interaction Type Interacting Agent Official Regulatory Outcome Restriction/Constraint
Pharmacodynamic Antagonism Erythromycin-containing products Reduced therapeutic effect (in vitro) Prohibited for co-administration.
Pharmacodynamic Synergism Neuromuscular Blocking Agents (NMBAs) Enhanced action of the NMBA Use with caution due to intrinsic neuromuscular blocking properties.
Exposure Modification Vitamin K Antagonists (VKAs) Increased INR and bleeding risk Requires frequent monitoring of coagulation tests.
Local Tissue Effect Other Topical Acne Therapies Cumulative irritancy effect Use with caution or avoidance; timing separation may be required.

Regulatory documentation establishes that Erythromycin-containing products are officially contraindicated for co-administration with Clindamycin due to demonstrable antagonism. Furthermore, Clindamycin’s inherent neuromuscular blocking characteristics may enhance the action of Neuromuscular Blocking Agents such as rocuronium and succinylcholine, necessitating careful use. When co-administered with Vitamin K Antagonists like warfarin, an increase in coagulation tests (PT/INR) has been reported, requiring mandatory monitoring of these parameters. No specific interactions with food, alcohol, or herbal products are explicitly documented in the official labeling for the topical formulation.

Mechanism of Action

How Clidets Works


The mechanism of action is defined by a dual pharmacological effect, initiated by the active molecule Clindamycin following the hydrolysis of its pro-drug form. The primary mechanism is the interference with bacterial protein synthesis. Clindamycin achieves this by reversibly binding to the 23S ribosomal RNA within the 50S ribosomal subunit . This binding inhibits peptide bond formation and translocation, producing a bacteriostatic effect that limits the proliferation of susceptible organisms and results in a reduction of the microbial population.

The secondary mechanism influences local inflammatory pathways. This involves a decrease in bacterial-derived pro-inflammatory metabolites and direct functional effects on host immune cells. This dual action influences the physiological response in the tissue and contributes to adjusting the local inflammatory state. The mechanism's effectiveness is constrained by acquired bacterial resistance, specifically through target site modification where erm gene-mediated methylation of the 23S rRNA prevents high-affinity binding, resulting in the failure to inhibit microbial proliferation in that context.

Dosage and Administration Information

The application of Clidets is defined by its use as a topical antimicrobial agent. The medicine is supplied in various formulations, including a 1% solution, gel, or lotion, all intended exclusively for cutaneous administration. Application involves dispensing a thin film of the product, which is then applied to the entire affected area of the skin, rather than being focused solely on individual lesions.

The standard frequency of administration is typically twice daily, though certain specific foam and gel formulations may be utilized once daily. Regardless of frequency, the treatment area is typically thoroughly cleaned and dried before the product is applied. For liquid or lotion dosage forms, the container is shaken well immediately prior to use to ensure even distribution of the active ingredient.

In terms of duration, continuous application for several weeks to months is often required before the full effects are observed. Treatment typically does not exceed 12 weeks of continuous use without a re-evaluation of the necessity for ongoing therapy. Specific parameters are noted regarding age: the safety and effectiveness of Clidets have not been established for use in pediatric patients younger than 12 years of age. Furthermore, administration requires care to avoid contact with sensitive areas, such as the eyes and mucous membranes.

Recent Clinical Evidence

Research evidence / Overview of studies for Clidets

Evidence for Use in Mild to Moderate Inflammatory Acne Vulgaris

The primary research for Clidets (topical clindamycin phosphate) was studied in the context of mild to moderate inflammatory acne vulgaris, a condition where symptoms often vary in intensity. This evidence base largely rests on Randomized Controlled Trials (RCTs), a common type of study used to evaluate medicines. These trials mainly included adolescents and adults. Researchers in these studies focused on measuring outcomes linked to inflammatory or irritative states, specifically the counting of inflammatory blemishes known as papules and pustules. They also used standardized tools, such as the Investigator's Global Assessment (IGA), to rate the observed global severity.

Studies reported measurements over defined time intervals, typically ranging from 8 to 12 weeks. Research describes data related to lesion counts over the observation periods. Systematic reviews that combine these studies describe findings from short-term RCTs. These analyses report consistent findings in the measured outcomes for inflammatory lesions over these shorter durations.


Study Design and Comparison

The clinical evaluation of Clidets was evaluated in trials utilizing various designs. Many of these trials utilized a vehicle control, which is a preparation containing all ingredients of the medicine except the active drug itself. Research examined what measurable differences, if any, could be observed in the study population when comparing the active medicine against the vehicle. Some research was observed in trials that compared Clidets against other single-ingredient topical medicines commonly used for this condition, or against the inactive vehicle. These comparisons provide data within the broader evidence landscape.


Long-Term Research and Follow-up Durations

Most of the foundational research was evaluated in short-term studies with follow-up durations usually lasting between 8 and 16 weeks. These short-term trials are relevant in trials assessing short-term or episodic symptom patterns. For longer observation, open-label extension studies have been used. These studies examined the use of the medicine, with some research exploring periods up to six months or, in a few instances, up to a year, to assess outcomes related to patient-reported experiences. Data describing outcomes across multiple years are still emerging.


Evidence in Different Study Populations

The evidence base for Clidets primarily reflects findings from studies on adolescents and adults who have mild to moderate forms of acne. These are the main groups where the drug was studied. Data for certain groups remain limited, specifically for populations like young children (under 12 years of age) or older adults, as they were not the primary focus of the foundational clinical trials.


What is Still Uncertain About the Research

Scientific literature acknowledges several research limitation frames concerning the evidence for topical clindamycin monotherapy. One area noted by researchers involves the study of antibiotic resistance development when the medicine was observed in patients over extended periods. Fixed-dose combinations with other active ingredients are also examined in research.

Furthermore, long-term effects are not fully established, as the follow-up durations were limited in many pivotal trials. While there are numerous studies, comparative evidence is lacking for direct, high-quality comparisons against every newer, complex topical combination treatment currently available. Evidence highlights what is known and what is still uncertain about this medicine.

Frequently Asked Questions (FAQ)

Common questions about Clidets (FAQ)


Q: How quickly does Clidets start to work after taking it?

Studies and official information indicate that the full, observed effects of Clidets often require continuous application for several weeks to months. Research outcomes are typically examined over defined time intervals, such as 8 to 12 weeks. This information indicates that the full benefit is gradual and may not be immediately visible upon starting use.


Q: Can Clidets be taken by older people or seniors?

Official prescribing information indicates that clinical studies did not contain enough subjects aged 65 and over to definitively compare responses to younger adults. However, other reported clinical experience has not identified differences in therapeutic responses or safety concerns between elderly and younger patients.


Q: What is the biggest difference between Clidets and other similar drugs I've heard of?

Clidets is an antibiotic that belongs to the lincosamide pharmacological class. A key distinguishing factor is that its active ingredient, Clindamycin Phosphate, is formulated exclusively for topical use on the skin. This classification and targeted application method set it apart from systemic treatments.


Q: Are the side effects of Clidets permanent?

The official labeling does not specify that the common skin-related side effects are permanent. For the most severe safety concern, colitis, official warnings note that symptoms can have a delayed onset, sometimes appearing several weeks after the medicine has been stopped. This information draws attention to the potential for a delayed risk.


Q: Why do doctors prescribe Clidets instead of other treatments?

The medicine is officially indicated for the treatment of mild to moderate inflammatory acne vulgaris. Its utility is based on its dual effect as a topical antibacterial agent and its influence on local inflammatory pathways. These documented mechanisms support its use as a targeted treatment for susceptible organisms.


Q: Do I need any special monitoring tests while taking Clidets?

According to the official product information, no routine laboratory monitoring is generally recommended for patients using the topical formulation. However, specific monitoring may be required if the medicine is co-administered with certain interacting agents or in patients with pre-existing kidney or liver impairment.


Q: Is Clidets considered a high-risk medication?

The official labeling carries a prominent warning regarding the potential for a severe adverse reaction known as Pseudomembranous Colitis. This risk is associated with the systemic absorption of clindamycin, and this classification of risk requires careful consideration.


Q: Are there any long-term side effects noted in the research for Clidets?

Most foundational clinical trials that examined Clidets were short-term, typically lasting 8 to 16 weeks. While the long-term effects are not fully established due to these limited follow-up durations, the post-marketing surveillance reports indicate that long-term adverse effects were not common in the clinical trials that were conducted.


Q: Is it okay to drive or operate machinery while taking Clidets?

Official regulatory documents state that no effects on the ability to drive or operate machinery have been observed with the use of this medicine. This information is based on controlled studies and safety reporting.


Q: Do I need a prescription to get Clidets?

Clidets is classified as a prescription-only medicine (Rx). According to regulatory standards in the United States and many other jurisdictions, this medicine cannot be purchased over the counter.


Q: How long does Clidets stay in your system?

Because Clidets is a topical formulation, the systemic absorption into the bloodstream is minimal. The elimination half-life for the topical formulation is therefore not known. For the oral form of Clindamycin, the half-life is typically reported as 2 to 3 hours in adults with normal organ function.


Q: Is it normal to feel tired after starting Clidets?

Although not listed among the very common side effects, symptoms of unusual tiredness or weakness have been reported. This information is noted in the official adverse reaction data for the medicine.


Q: What happens if I miss a dose of Clidets?

Official patient instructions describe applying a missed dose as soon as it is remembered. If it is almost time for the next scheduled application, the missed dose should be skipped entirely. The regulatory information indicates that double or extra doses are not to be taken.


Q: Does Clidets interact with common pain relievers like ibuprofen or acetaminophen?

Official drug interaction checkers and regulatory documents do not list a direct interaction between the topical formulation of Clidets and either ibuprofen or acetaminophen. The minimal systemic absorption of the topical formulation generally limits the risk of systemic pharmacokinetic interactions.


Q: Is there a generic version of Clidets available?

Yes, the active ingredient in Clidets, Clindamycin Phosphate, is widely available on the market. It is often dispensed in generic formulations under its chemical name.


Q: Can Clidets cause weight gain or weight loss?

Weight loss has been reported as a symptom associated with the severe safety concern of antibiotic-associated colitis, which is a possible complication of clindamycin use. It is important to note that weight changes are not listed as a common primary side effect of the topical medicine itself.


Q: Does Clidets interact with hormonal birth control?

Regulatory information notes that Clindamycin, the active ingredient, may reduce the effectiveness of some hormonal birth control products that contain ethinyl estradiol. This information describes a potential interaction that could increase the risk of pregnancy.


Q: What should I do if I feel like Clidets isn't working?

The full effect of the medicine is often not observed until several weeks to months of continuous use. Official guidance describes informing a healthcare provider if symptoms do not begin to improve or if they worsen after a period of use.


Q: Can Clidets make me dizzy or lightheaded?

Dizziness has been reported in post-marketing surveillance for the topical formulation of the medicine. While this symptom is noted in official records, it is not listed among the most common side effects.


Q: Can I stop taking Clidets suddenly?

Official patient instructions recommend that the medication be used for the full course as directed. Official patient instructions indicate that stopping use is not recommended unless instructed to do so by a healthcare provider.


Q: Does Clidets work the same way for everyone?

The effectiveness of Clidets is conditional and can be limited by factors such as acquired bacterial resistance. This occurs through a modification of the ribosomal binding site, which is an official mechanism that prevents the drug from inhibiting microbial proliferation.


Q: Does Clidets change how my body metabolizes other drugs?

Clindamycin is primarily metabolized in the liver by a specific enzyme system known as CYP3A4. The fact that Clindamycin uses this pathway is the basis for potential interactions with other drugs that are also processed by the same enzyme system.


Q: Is Clidets a controlled substance?

Clidets is classified as a prescription-only medicine (Rx). According to regulatory classification documents, this medicine is not scheduled as a controlled substance by the Drug Enforcement Administration (DEA).


Q: What does the FDA label say about Clidets?

The FDA labeling provides the authoritative information on the medicine's officially approved use, mechanism of action, and known side effects. This document also contains all mandated warnings, such as the risk of colitis, and lists the specific contraindications (e.g., the age restriction for use).


Q: Can Clidets affect my mood or mental health?

The official listing of adverse reactions includes postmarketing reports of central nervous system symptoms associated with the antibiotic class, such as irritability and agitation. The frequency of these specific symptoms is not known for the topical formulation.

How should Clidets be stored and disposed of?

How to Store and Dispose of Clidets?

Storage Requirements

Clidets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from light and moisture and must not be frozen. To maintain product integrity, Clidets must be kept in its original container and the container must be kept tightly closed.

Child Safety and Disposal

It is a mandatory safety requirement to keep Clidets out of the sight and reach of children.

Disposal of any unused or expired product must be performed according to local regulations and requirements. It is essential not to flush this medication down the toilet or pour it down a drain unless a governmental take-back program explicitly instructs this method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clidets found in:

A-Z Index: